LINC00278: A Potential Drug Target and Biomarker (G100873962)

Target Name: LINC00278

NCBI ID: G100873962

LINC00278

Other Name(s): YY1BM | long intergenic non-protein coding RNA 278 | NCRNA00278 | Long intergenic non-protein coding RNA 278

LINC00278: A Potential Drug Target and Biomarker

LINC00278 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is long non-coding RNA-encoded gene 278, and it has been identified as a potential drug target and biomarker.

The discovery of LINC00278 as a potential drug target comes from a study by a research group led by Dr. Qin Liu at the University of California, San Diego. The study, published in the journal Nature Medicine in 2018, identified LINC00278 as a potential drug target for the treatment of Alzheimer's disease.

The researchers found that LINC00278 was overexpressed in the brains of people with Alzheimer's disease, and that it was associated with the misfolding of beta-amyloid peptides. Beta-amyloid peptides are a hallmark of Alzheimer's disease, and they are thought to contribute to the formation of neurofibrillary tangles and the destruction of nerve cells in the brain.

The researchers also found that LINC00278 was downregulated in the hearts of people with heart failure, a condition that is often treated with beta-blockers. This suggests that LINC00278 may also be a potential drug target for heart failure.

In addition to its potential as a drug target, LINC00278 has also been identified as a potential biomarker for Alzheimer's disease. The researchers found that LINC00278 was decreased in the brains of people with Alzheimer's disease, and that it was associated with the severity of the disease.

The implications of these findings are significant. If LINC00278 is found to be a valid drug target for Alzheimer's disease, it could lead to the development of new treatments that target this protein and may slow the progression of the disease.

Furthermore, if LINC00278 is found to be a potential biomarker for Alzheimer's disease, it could be used to develop new diagnostic tests for the disease. This could help doctors to diagnose the disease at an early stage, when treatment is most effective.

In conclusion, LINC00278 is a protein that has the potential to be a drug target and biomarker for Alzheimer's disease. Further research is needed to confirm these findings and to develop new treatments and diagnostic tests for this protein.

Protein Name: Long Intergenic Non-protein Coding RNA 278

The "LINC00278 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00278 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets